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Objectives. The parpose of this study was to determine the safety and eikaey of thee dosiag regimens of intracoronary aroklnose for facilitated aagioplasty of cbroair total native coronary artery oedasions.
llac&md Percutaneoes translnminal coronary angioplasty of elaanidiy ocdaded (>3 moatbs) native coronary arteries is ass&&d with low initial sweess secondmy to an inability to pass the guide wire beyond the osdaslon.
htWods. Patients we emoiled if a duwdc total o&sion >3 namths old mnki not be crossed with stundnrd angioplasty equipment. Of the 101 patients enrow 41 bad saccessfnl pide wire passage and were exdaded hrn omkinase treatment. Tbe remabdng 60 patients were randomized to receive oae of three intromnmay dosing tqimens of q rokinase over 8 b (group A = ~~U;lgoopB=l~miflmoU;~pC=32milliwU), and angioplosty was ag0b1 attempted after completion of the nmbhmse~ins8patleItts.
lledfs. Connauy angioplasty was saceeshl in 32 patients (53%) (group A 52%, group B SO%, group C 5970, p = 0.86). Tbis study had a 90% power to detect at least a 50% difference between dosing groups at alpha 0.05. Bleeding complications reqniring bloud transfusion did not differ sign&a&y amang the dosing gruups (A O%, B lS%, C 6%, p = 0.14), although major bleeding episodes were less common in groap A (p c 0.05). There were nojor fnwedaral or in-hospital complications. Angi~pbic follow-up in 69% of tbe patients with soecessfui angioplasty revealed target vessel patency in 91% bat an angiograpbic restenosis rate of 59%.
CapclkdaRF. A prolonged suprawktive intracoromq iofasion of urokinase can be safely administered and may facifiite angioplasty of chronic total occlusions. Lower doses of aroldnase are equally etktive and result in fewer bleeding mmplications than do bigber dosage re@nens. Vessel patency is keqaently maintain* bat restenosis remains a problem.
(JAm cd Izhdiol199@27: Conventional percutaneoas translaminal coronary angioplasty of chronically occluded native coronary arteries has been associated with lower initial success rates as well as higher restenosis rates than those associated with elective angioplasty of nonoccluded vessels (I). Reported initial success of angioplasty of chronic total occlusion rates range from 47% to 67% (mean t SD 61 2 7%) (l-7). However, the study patients were highly selected and many of these series included patients with s&acute (<I month) or functional (99% stenosis) occlusioas, which are associated with better primary success rates. Even after successful balloon angioplasty, t&month angiographic restenosis rates range from 41% to 71% (mean 54 i: 11%) and reocclusion rates range from 20% to 40% (5-9).
The most frequent cause for failure of angioplasty in :hronic total occlusions is the inability to cross the occlusion with a guide wire, particularly in occlusions of >3 months' duration (1411). Reported success rates in this subgroup are consistently lower than those associated with more recent total occlusions and have ranged between 0% to 55% (12, 13) . Because of the low probability of success, chronic total occlasions of >3 months' duration are usually not considered for percutaneous intervention, and are often referred for bypass surgery. However, successful recanalization of chronic total occlusions has been shown to reduce angina1 symptoms, decww the need for coronary artery bypass surgery and improve left ventricular function (5, 14 24-h ) infusion coukl be safely perIomed and appeated to facilitate passage of the guide wire (17). The present larger prospective, randomi-:ed trial was performed to determine the safety and efficacy of three dosing regimens of intracoronary uroliinase for chronic total native corona9 artery occlusions when guide wire passage beyond the lesion could not be achieved.
Methods Stu~$ patients. The study group was composed of 101 patients undergoing elective corona9 augioplasty of a chronic occlusion in a native corona9 artery. These patients had Canadian Cardiovascuhu Society class II to IV angina or a reversible myocardial perfusion defect in the distribution of a corona9 occlusion, or both. Inchtsion criteria included a chronic occlusion of >3 months' duration as assessed by previous cardiac catheterization, change in angina1 symptoms or a prior failed angioplasty attempt. To ensure adequate delivery of urokinase to the point of occlusion, patients with a large side branch or with extensive bridging collateral vessels at the point of occlusion were excluded. Additional exclusion criteria included contraindication to thrombolytii therapy (histo9 of cerebrovascular accident, known bleeding disorder, severe uncontrolled hypertension, major surge9 or trauma within 60 days), chronic atrial fibrillation with underlying mitral valve disorder, and inability to advance the infusion catheter to the proximal portion of the occlusion. The study protocol was approved by the Institutional Review Board of William Beaumont Hospital and written informed consent was obtained from each patient before recruitment.
Urokinase protoml Patients were pretreated with 325 mg of chewable aspirin and received a bohrs of 10,000 U of intravenous heparin, with additional bohrses given to maintain an activated clotting time >300 s. Patients scheduled for a urokinase infusiin wem brought to the catheterization lahorato9 in the morning and an attempt was made to cross the occlusion with a guide wire. A 7P guiding catheter was inserted through the femoral artery and seated in the ostium of the occluded corona9 artery. A Touhy-Rorst adapter (ACS) was attached to the end of the guiding catheter and a 0.0~in. (0.O96-cm) Cragg infusion wire (Meditech) was advanced over a O.Ol&in. (0.04ka) guide wire. Guide wires of increasing stitbress (Intermediate and Standard wires) were employed and an 0.018-m. standard wire was attempted before instituting the urokinase infusion in all cases. The 41 patients whose lesions were successfully crossed were excluded, whereas the remaining 60 patients whose occlusion could not be crossed were randomized to one of three urokinase. dosing regimens. Contrast medium was injected through the Cragg wire to ensure that it was embedded in or just proximal to the occlusion. Intracorotuuy urok&se (Abbofrinase, Abbott Iaboratories) was then infused for approximately 8 h through the guidingcatbeterpmxim&yandtheCragginfurkwiredii taUy. With the use of sealed randomixation errvelqKs Patients ~rn~~~~~~~~~ regimensofm0kinme.Ur0l&sed0aeswerederivedfrom prevbusstudieausingurokiMseinfusioosinocdudedsaphe-ZIDAR ET AL 1407 UROKJNASE IN CHRONIC TOTAL OCCLUSIONS nous vein grafts. The duration of infusion was limited to 8 h to reduce the bleeding complications of a 24-h intusion and to maintain catheterization laboratory convenience. Group A received SO,OUO U/It of urokinase through the guide catheter and 50,000 U/h through the Cragg infusiin wire for a total of SOO,ooO U over 8 h. Group B received 100,000 U/h through each port for a total of 1.6 mdlion U over 8 h. Group C received 200,GfKl U/h through both the guide and the infusion wire for a total of 3.2 million U over 8 h. The catheter and the femoral sheath were sutured to the skin to ensure stabiity and were covered wtth a s&l; dressing
Patients were then monitored in the cardiac care unit while intravenous heparin and intracorona9 urkinase infusions were continued. A broad spectmm intravenous antibiotic agent was administered during the urokinase infusion. The patient's hemoglobin, fibrinogen, fibrin split products, creatinme kinase, activated clotting time and partial thromboplastin time were monitored. Activated clotting time was maintained between u10 and 250 s while the patient was in the cardiac care unit. After -8 h, the patient returned to the catheterization laboratory for a second attempt to cross the occlusion. A similar approach, using wires of increasing stilfness, was again employed. If the le+on was sUCCeSSfUlhl cmssed, balloon angio plasty was performed. No other interventional devices were used during the primary procedure. Procedural success was defined as successful guide wire passage and a final residual diameter stenosis <50% with Thrombolysis in Myocardial Infarction (TIMI) grade 3 llow. Clinical success was defined as procedural success without a major in-hospital cardiac event.
FoIIow+p. If the procedure was sllecesw admiistratiotl of warfarin was initiated and continued for 3 to 4 months (prothrombin time was maintained between 18 and 22 s, international normal&d ratio 20 to 3.0), treatment with aspirin was mtinued and additionaI medic4 therapy was adminktered at the discretion of the cardii Patients with sucuMulcoronaryangi0plastyaftertheur0kinaseimWon were followed up cbically and were quested to undergo an elective stress thalhum test at 3 months and a folhnv-up catheterizition at 6 months. Clinkal resteriosis was defined as death or the need for target vessel revduring the S-month follow-up period divided by the total number of successful angioplasties. Angiogqhk restenosis was delined as>5O%diameterstenosisbyquantitatbeangmgmphyinthe target Iesion at follow-up. bQ%tWcaI aMI+. Immedkte procedural resuk'and complications were compared among the umkinase dosing groups AU data are dkphyed as a mean value 2 SD. Signiseanoetestingwasperformedbyusinganafysisofvariaxe (ANOVA) testing where appropriate. Statistii signifcam was accepted at the p < 0.05 level.
protocol. Although 101 patients gave consent to enter the study, 41 patients did not recei\, urokinase and were excluded secondary to successful crossing of the occlusion with the Fide wire on the initial attempt (n = 37), contraindications to thrombolytic therapy (n = 2) or inability to track the infusion catheter into the occlusion (n = 2). Si patients had unsuccessful angioplasty and were then randomized to receive umkinase infusions. Two patients, both randomized to group C, required early discontinuation of the urokinase infusion. One patient experienced a transient ischemic attack during placement of the infusion catheter, although this was not recognized until the urokinase infusion was initiated. The other patient experienced gastrointestinal bleeding after 30 min of urokinase infusion, attributed to a Mallory-Weiss tear secondary to vomiting that began after the left ventricu@ram was performed. Baseline patient demographics for the 60 patients randomized are shown in Table 1 .
The mean age of the patients was 56 2 10 years and the mean duration of occlusion was 23 + 16 months. The chronic occlusion was located in the left anterior descending coronary artery in 27%, the leti circumflex coronary artery in 13% and the right coronary artery in 60%. The majority of patients had multiple cardiac risk factors and 33% had prior revascularization. Fifty-two percent of patients had a prior documented myocardial infarction in the distribution of the occluded target vessel. Eighty-seven percent had at least class II angina1 symptoms at the time of the procedure, whereas 13% had angina-equivalent symptoms (shortness of breath, fatigue) and positive findings on a functional test. Pmcedural results. All patients had TlMI grade 0 flow at the start of the procedure. Fifty-eight patients (97%) completed the urokinase infusion and returned for repeat angiography and attempted coronary angioplasty. The urokinase infusion improved flow from TIM1 grade 0 to TIM1 grade 1 in only 5 patients (9%). Despite the lack of angiographic improvement with urokinase, the guide wire was successfull! passed in 34 cases (59%); however, two patients were not considered to have had successful angioplasty because of a residJ 50% to 70% stenosis and TIMI grade 2 flow. Therefore, angioplasty was successful in 32 patients (53%) after the urokinase infusion (Fig. 2) . Balloon angioplasty success rates for groups A, B and C were 52%, 50% and 59%, respectively (p = 0.86, chi-square = 0.31, df = 2) ( Table 2) . A power analysis assuming alpha = 0.05 revealed that the study had a 90% power to detect a ~50% difference between the groups. Differences between angioplasty success rates for the three major coronary vessels were also not statistically significant (p = 0.9J.
Complications.
There were no major procedural complications including stroke, need for emergency bypass surgery or death, yielding a clinical success rate of 53%. Chest pain occurred in 20% of patients during the urokinase infusion; however. only one of these patients had ischemic electrocardiographic changes. Two patients (3%) had an embolic event manifested by transient visual disturbances-one patient before and one after the urokinase infusion was initiated. Nonflow-limiting disseaions in 30% of patients were the o&y Figure 2 . Selective angiograms of the right coronary artery demonstrating total occlusion of the distal artery (armw, left pauel). After urokinasc was infused for 8 h, angioplasty was successful, with a 10% residual s:enosis @raw, center paael). Six-month follow-up an&ram (right panel) demonstrates a patent vessel without restenosis.
angiographic complications.
All patients who had unsuccessful angioplasty attempts had an uncompliczted hospital course without major complications.
There were no cases of abrupt vessel closure or recurrent in-hospital ischemia necessitating repeat intervention. Three patients (5%) exhibited elevated levels of creatine kinase, ME fraction after the procedure, b-&i a level diagnostic of myocar dial infarction (elevation >3 times normal) occurred in only one patient (1.6%). Four patients (7%) had bleeding complications requiring a blood transfusion; all of these complications were attributed to blood loss at the vascular access site. Transfusion requirements did not differ significantly among the groups (A O%, B 15%, C 6%, p = 0.14). Gastrointestinal bleeding not requiring blood transfusion occurred in three patients (5%); two of the three had heme-positive stools and one patient had a Mallory-Weiss tear. Hematuria also occurred in two patients (3%). Combined bleeding complications including groin bleeding requiring blood transfusion, gastrointestinal bleeding and hematuria were more common in group B (25%) and group C (24%) than in the lowest dosing group A (4%) (p < 0.05 for group B or C vs. group A). Minor groin bleeding (hematomas) not requiring blood transfusion occurred more frequently in the higher dose groups (A 3570, B 43%, C 60%, p = 0.2) hut differences were not statistically different.
Follow-up. Twenty-nine of the 32 patients with successful coronary 'angioplasty after the urokinase infusion underwent functional stress testing at 3 months. Of these patients, 18 had no evidence of &hernia in the distribution of the target vessel, 4 had fixed defects and 7 had reversibte perfusion abnormalities. Six-month angiograms were performed in 22 (69%) of the 32 patients. The remaining 10 patients refused angiographic follow-up but were asymptomatic and had negative resuits on functional tests. Target vessel patency. defined as L stenosis ~100% and TIM1 grade 3 flow, was maintained in 20 (91%) of the 22 patients with follow-up angiography.
However, angiographic restenosis, defined as a residual diameter stenosis >.50%, was seen in 13 (59%) of the 22.
Clinical 6-month follow-up cn the 32 patients with procedural success was achieved in 97%. Symptom improvement was evaluated zt 6 months by a practitioner who had no knowledge of coronary angioplasty results. A decrease in angina class or improved exercise tolerance was noted in 28 (63%) of the 32 patients with angioplasty success. There were no recurrent myocardial infarctions, strokes or deaths in the &month follow-up period. Clinical restenosis defined as the need for target vessel revasctdarizatioc occurred in 13 patients (41%); elective bypass surgery was performed in 2 (6%) of these patients and repeat target vessel angioplasty in 11(34%). The 6-month survival rate was 100%: of patients who underwent angiographic follow-up, 91% were ahi with a patent target vessel and 68% were alive without the need for a repeat revascularixation procedure.
Of the 28 patients who had umuccessfid angiophtsty after the urokinase infusions only 4 (14%) noted a decrease in angina class or improved exercise tolerance. F&nv-up data for ail 60 patients who underwent attempted angioplasty after administration of urokinase demonstrated repeat percutaneous interventions in 11 (18%) bypass surgery in 9 (15%) and death in 0%. The majority (seven of nine) of the bypass operations were performed in patients who had unsuccessful angioplasty.
Discussion
A prolonged infusion of uro!Gmse has proved effective in the recanalitation of chronic total ozdusions in peripheral arteries and saphenous vein bypass grafts (15,16). A pilot study (17) ezamhting this approach for native coronary arteries demonstrated both safety and efficacy; however, the 24-h infusion utilized was costly and uncomfortable for the patient. Previous reports (18,19) have also documented the success of thrombolytic infusions for coronary angioplasty of chronic total occhnions. We were able to demonstrate that an 8-h infusion of intracoronary urokie?se can frequently facilitate balloon angioplasty of chronic total occlusions >3 months old. RationaIe for recadhation of chronic total occlusions. Chronic total occhtsions are the most frequent reason for angioplasty faihue and referral for elective bypass surgery (5). Although many patients have had myocardial damage in the distriiution of the occluded artery, collateral channels often maintain myocardial viability (20) (21) (22) . If the total occlusion occurs in a highly diseased segment of the blood vessel without prior myocardial infarction, the collateral vessels also maintain viability, but the patient presents with a change in angina pattern (23). These collateral vessels usually supply sufficient blood flow to the affected area during times of physical inactivity but frequently become insutlicient when ozygen demand is increased (20). Many patients therefore develop life style-limiting angina that is often refractory to mazimlzed medications. Accordingly, attempts to treat chronic total occlusion with angioplasty are common and corrprise 10% to 20% of all angioplasty procedures performed (24) . The rationale for recanalization of chronic total occlusions includes the lessening of clinical symptoms (13), a decreased need for bypass surgery (9,13), possible improvement in left ventricular function (14, 25) and improved survival (6) . Decreased long-term survival is reported in patients with a chronic total occlusion of a single vessel treated medically (3, 26) , and a total occlusion has been associated with a higher incidence of sudden death than that of a high grade stenosis (27) . m The composition of the chronic total occlusion has been shown to include a fibrocalcitic atherosclerotic plaque and various degrees of organized thrombus (28). In amtmst, fresh occhtsions during myocardial infarction are composed of a ruptured fibrous cap overlying soft atheroma and a fresh, soft occlusive thrombus (29) . In the chronic ocdusion, layers of thrombi of different ages may be present, each of which is associated with fibrointimal proliferation (28). The age and the degree of fibrosis associated with the most recent thmmbus is the single most important factor determining the likelihood of successful balloon recanalization (l,2, 6, 14, 23, 30, 31) . Attempts to pass a guide wire through t&e Iesians often lead to mcanahmtion of false lumens and ~~t~e~inthearterialwall.Wehadhopedto tt& advantage of utokinase's known abiity to activate ilbrinassociiltwi with thrmbus, to lyse the toftheocdusionaudrestoreanterograde ~~~~~~.~~~~d~~~e afteradministrationofur~ ~~~~~ to soften the lesion, allowing passage of the guide wire. This effect is presumably due to partial lysis of the "freshest" thrombus occlcding the lumen. Success. Urokinase was able to facilitate angioplasty of chronic total occlusions in 55% of cases othenvisc categorized as angioplasty failures. The urokinase infusion increased the angiopllmty success rate for the 101 patients recruited from 41% to 72%, a rate that compares favorably with that of previous reports (1,2,11-13.32) on angioplasty of &tonic total occlusions >3 months old. Because of the enrollnent requirement of failed wire passage on initial attemg:; L arteries underwent significant manipulation before urokinase administration. This factor probably led to an increased rate of vessel disruption and a higher dissection rate after angioplasty success was finally achieved. It is possible . that starting the urokinase infusion before wiring attempts may increase acute procedural success and decrease longterm complications.
Follow-up success. The return of symptoms with a hemodynamically significant restenosis when the original occlusion was total is not unusual. This is secondary to derecruitment of collateral vessels after the initial successful angioplasty procedure (32) . In contrast to results in previous studies (8, 9) on chronic total occlusions, vessel patency was maintained in a high percentage (91%) of cases. All patients who did not undergo angiographic follow-up were asymptomatic with neg at@e results on functional tests. Nevertheless, a high rate of angiographic restenosis was observed, which is consistent with previous studies (1,5,6,23,30). Given the high incidence of restenosis reported for these lesions, stent placement may be u&id. Stems have been shown to reduce restenosis rates for elective angioplasty of native coronary arteries (33) and would probably also decrease long-term complications after angioplasty of chronic total occlusions.
Recommeudations. Major complications including bleeding requiring transfusion were uncommon, making this approach to chronic total occlusions relatively safe. The two neurologic events (transient ischemic attack rate 3%) are of some concern; however, only one event occurred aher initiation of urokinase. Patient immobility during the urokinase infusion is critical to minimizing bleeding complications, and adequate sedative and pain medications need to be administered to maximize patient comfort Minor bleeding complications were more common in the higher dose groups, hut success rates did not differ signiticantly among groups. Therefore, on the basis of our results, 50,006 U/h per port would be the dosage of urokimx recommended for this procedure. Because of the increased likelihood of vessel disxction after numerous wiring attempts, the urokinase infusion should probably be started before vigorous attempts to pass the guide wire beyond the occhtsion. If recanalization is achieved, consider&on should be given to stent placement in an attempt to lower reocdusion and restenosis rates . . . Larrutattoasoftkeatudy.ourstudyhasfourptincipal Iimitath 1) By flefinitio~ all patients who were emolled had Therefore, withii the de-signed protocol, it was not possible to compare urokinase infusion with an infusion of placebo. Theoretically, the wiring attempts may have been more aggressive after the urokinasc infusion or the heparin infusion may have been responsible for the increased success rates. This effect would have led to a falsely increased need for urokinase and cannot be ruled out because of the study design. Although our trial did involve randomization to different urokinase dosing regimens, there was no placebo infusion group. Because of this limitation, we cannot conclusively prove that the success after the infusion was solely the result of urokinase administration. However, before initiation of urokinase, all patients had failed attempts with an O.Ol&in. standard wire which was considered failed ang'.oplasty by current standards in our cath laboratory.
2) Angioplasty equipment has bxome more sophisticated since initiation of this sturdy. The more common use of the O.Ol&in. glide wire and laser-assisted guide wires may increase our ability to cross chronic total occlusions. Both of these new technologies, however, also increase the likelihood of finding false lumens possibly leading to an increased dissection or perforation rate, or both.
3) The sample size of 60 patients is relatively small, and further validation studies with larger patient groups are probably warranted. Nevertheless, urokinase was necessary for facilitation of angioplasty in 5% of cases, resulted in few bleeding complications, and it is currently recommended in light of this study's results, despite the fact that thii study was obsetvational without a placebo control group. 4) Although urokinase was the thrombolytic agent chosen for this study, other lytic agents includii strcptokinase or recombinant tissue-type plasminogen activator may have led to similar success rates. Testing of these other agents in comparison with urokinase will need to be done in future randomized studies.
Ckmhhm.
An g-h supraselective intracoronary infusiin of urokinase offers the interventional cardiologist a treatment option in the rxanathzation of symptomatic total occlusions Sat have been unsuccessfully treated with prior angioplasty attempts with standard interventional techniques. Procedural success was achieved with lower dose regimens and was associated with less bleeding compliitions. Although vessel patency was frequently maintained, angiographii restenosis remains a problem. Nevertheless, the urokinase infusiin significantly increased the overall rate of angioplasty success in chronic total occlusious >3 nonths old and lessened symptoms in a large majority rf pari::its.
